Market News / Story
BioNexus Gene Lab Lands Exclusive Malaysia CogniAI Licence; 10-Year Term, 10% Royalty, 560,000 Shares
·
BioNexus Gene Lab entered into a CogniAI Healthcare Licence and Strategic Collaboration Agreement with Ruanyun Edai Technology to secure an exclusive licence for Malaysian healthcare, with rights to develop, brand and sublicense applications. At closing, BioNexus will issue 560,000 common shares to RYET, including 410,000 shares for the stated $3.5 million licence consideration and 150,000 shares in exchange for 500,000 RYET ordinary shares. The 10-year initial term…